William Blair Investment Management LLC Sells 3,738 Shares of Inspire Medical Systems, Inc. (NYSE:INSP)

William Blair Investment Management LLC lowered its position in Inspire Medical Systems, Inc. (NYSE:INSP) by 0.4% during the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 902,611 shares of the company’s stock after selling 3,738 shares during the period. William Blair Investment Management LLC owned 3.01% of Inspire Medical Systems worth $167,326,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also added to or reduced their stakes in the company. B. Metzler seel. Sohn & Co. Holding AG bought a new position in Inspire Medical Systems in the third quarter worth approximately $1,929,000. Smartleaf Asset Management LLC boosted its holdings in Inspire Medical Systems by 178.9% in the fourth quarter. Smartleaf Asset Management LLC now owns 357 shares of the company’s stock worth $66,000 after acquiring an additional 229 shares in the last quarter. Thrivent Financial for Lutherans boosted its holdings in Inspire Medical Systems by 39.7% in the third quarter. Thrivent Financial for Lutherans now owns 110,580 shares of the company’s stock worth $23,337,000 after acquiring an additional 31,444 shares in the last quarter. Merit Financial Group LLC bought a new position in Inspire Medical Systems in the fourth quarter worth approximately $313,000. Finally, Public Employees Retirement System of Ohio boosted its holdings in Inspire Medical Systems by 9.4% in the third quarter. Public Employees Retirement System of Ohio now owns 36,361 shares of the company’s stock worth $7,674,000 after acquiring an additional 3,125 shares in the last quarter. Institutional investors own 94.91% of the company’s stock.

Insiders Place Their Bets

In other news, CTO John Rondoni sold 583 shares of the firm’s stock in a transaction on Tuesday, February 11th. The stock was sold at an average price of $170.49, for a total value of $99,395.67. Following the completion of the transaction, the chief technology officer now directly owns 10,424 shares of the company’s stock, valued at $1,777,187.76. This trade represents a 5.30 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, insider Randy Ban sold 25,584 shares of the firm’s stock in a transaction on Thursday, February 13th. The stock was sold at an average price of $183.50, for a total value of $4,694,664.00. Following the completion of the transaction, the insider now directly owns 7,259 shares of the company’s stock, valued at $1,332,026.50. The trade was a 77.90 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 26,225 shares of company stock valued at $4,806,530 over the last ninety days. 4.10% of the stock is currently owned by insiders.

Inspire Medical Systems Trading Up 2.2 %

Shares of INSP opened at $162.26 on Monday. The company has a market capitalization of $4.81 billion, a price-to-earnings ratio of 93.79, a PEG ratio of 2.86 and a beta of 1.48. The stock has a 50 day moving average of $184.92 and a 200 day moving average of $192.07. Inspire Medical Systems, Inc. has a 12 month low of $123.00 and a 12 month high of $257.40.

Inspire Medical Systems (NYSE:INSP) last released its earnings results on Monday, February 10th. The company reported $1.15 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.74 by $0.41. Inspire Medical Systems had a return on equity of 8.19% and a net margin of 6.67%. As a group, equities research analysts predict that Inspire Medical Systems, Inc. will post 2.16 earnings per share for the current year.

Analysts Set New Price Targets

Several research analysts have issued reports on INSP shares. Piper Sandler cut their price target on Inspire Medical Systems from $260.00 to $233.00 and set an “overweight” rating on the stock in a report on Monday, February 10th. KeyCorp reissued an “overweight” rating and issued a $234.00 price objective (down from $236.00) on shares of Inspire Medical Systems in a research note on Friday, January 24th. Wells Fargo & Company lowered their price objective on Inspire Medical Systems from $198.00 to $195.00 and set an “equal weight” rating for the company in a research note on Tuesday, February 11th. Royal Bank of Canada reissued an “outperform” rating and issued a $260.00 price objective on shares of Inspire Medical Systems in a research note on Tuesday, February 11th. Finally, Bank of America raised Inspire Medical Systems from a “neutral” rating to a “buy” rating and increased their price objective for the stock from $220.00 to $255.00 in a research note on Wednesday, November 20th. Three analysts have rated the stock with a hold rating and eight have assigned a buy rating to the company’s stock. According to MarketBeat.com, Inspire Medical Systems currently has an average rating of “Moderate Buy” and an average target price of $228.82.

Inspire Medical Systems Company Profile

Inspire Medical Systems, Inc, a medical technology company, focuses on the development and commercialization of minimally invasive solutions for patients with obstructive sleep apnea (OSA) in the United States and internationally. The company offers Inspire system, a neurostimulation technology that provides a safe and effective treatment for moderate to severe OSA.